Plain-English translation of NCT06906874 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing whether — a type of supplement — can help people with end-stage kidney disease manage high phosphorus levels in their blood. High phosphorus is a common problem for people on hemodialysis and can damage blood vessels over time. The medication is being tested alongside the (standard kidney disease medications) you may already be taking.
People on dialysis almost always develop high phosphorus levels, which can lead to dangerous calcium buildup in blood vessels. Currently, doctors use calcium-based or other to control this, but they can have unwanted side effects. This trial is exploring whether the medication might work as well or better, with fewer side effects.
You likely qualify if…
You likely don't qualify if…
You will continue your regular hemodialysis schedule and take your standard phosphate binder medications. If assigned to the treatment group, you will also take capsules with your meals. Your blood phosphorus levels and overall kidney health markers will be monitored throughout the study to see if the medication helps control phosphorus more effectively than standard treatment alone.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
Egypt